In August, I reported:
First suggested here at $6.65 and then again at $5.50 or so, NPSP closed Friday at $22.59, for about a quadruple. I celebrated by taking some profits; yet Guru writes of the company’s wildly expensive drug ($295,000 a year): “There are probably 1,000 to 3,000 people in the US who could really benefit from Gattex. Could be more. That’s $300 million to $900 million in the US. They will launch in Europe where the market is similarly sized. For sure this is a $500 million in peak sales. Every year. For a long time. No competition. No one even trying to compete. This product could extend survival. Meanwhile, they have another product, for hypoparathyroidism — to supply the missing parathyroid hormone. Will file this year. Launch end of next year. Another $300 million potential market in the US. Then they get a royalty from Amgen of $100 million. The stock should hit 36 over the next year.” So I’ve kept some.
Yesterday, it closed at $35.11, which is close enough. I took my six-fold gain (thanks, Guru) and sold the rest.
Have a great day. I feel a political screed coming on, but for now, you’re spared.
Quote of the Day
It would be difficult to find any plausible argument for supposing that gold will weaken in dollar terms in the 1980s.~The Times of London, 12/12/79. Gold peaked 40 days later at $875, collapsed, and then trended gently down throughout the 1980s.
Request email delivery
- Nov 22:
Laugh Or Cry? It Is A False Choice.
- Nov 21:
All The Reasons We Should Believe Trump
- Nov 20:
The Corporate Tax Rates Are Too Damn Low
- Nov 19:
The Prices Are Just Too Damned High — And Here’s Why
- Nov 18:
Mugged by a 90-Year-Old?
- Nov 16:
Arms For Dirt
- Nov 15:
Plant A Tree — How Scientists Got It So Wrong
- Nov 14:
But Does It Rise . . . Part 2
- Nov 13:
But Does It Rise To The Level?
- Nov 12:
- Nov 22: